NovoCodex Biopharmaceuticals, a subsidiary of Shanghai-listed pharmaceutical main Zhejiang Medicine, has raised 400 million yuan (USD 62 million) in its Series A spherical to expedite the event of antibody-drug conjugate (ADC).
Source link
Article – Explorebit – ExploreBit